Chad Deal, MD Head, Center for Osteoporosis and Metabolic Bone Disease, Department of Rheumatic and Immunologic Disease, The Cleveland Clinic
James Gideon, MD, PhD Blanchard Valley Medical Associates, Findlay, OH
Address: Chad Deal, MD, Department of Rheumatic and Immunologic Disease, A51, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195
Dr. Deal has indicated that he serves as a consultant for and is on the speaker’s bureau of Eli Lilly and Company.
ABSTRACTForteo (teriparatide of rDNA origin), a genetically engineered fragment of parathyroid hormone, is the first of a new class of drugs to treat osteoporosis. The drug's anabolic action increases bone turnover, stimulating osteoblasts to a greater extent than osteoclasts, and reducing both vertebral and nonvertebral fractures. However, a number of issues about its use remain unanswered.